LXRX Key Stats
|Revenue (Quarterly YoY Growth)||-36.02%|
|EPS Diluted (TTM)||-0.219|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-111.58M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-13302%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Setback for Lexicon Pharma - Analyst Blog Zacks Dec 5
- Biotech Stock Roundup: CBST Hits 52-Week High, OREX Lights Up - Analyst Blog Zacks Dec 4
- Pre-Open Stock Movers 12/03: (OMED) (UNIS) (AAPL) Higher; (KKD) (CNAT) (ECTE) Lower (more...) Street Insider Dec 3
- Lexicon Pharma (LXRX) P2 Study Of LX1033 In IBS-d Not Statistically Significant Street Insider Dec 3
- Lexicon to Present at the Jefferies Global Healthcare Conference noodls Nov 15
- Lexicon Pharmaceuticals' Management Presents at 2013 Credit Suisse Healthcare Conference (Transcript) Seeking Alpha Nov 13
- With 'Progress' Like Lexicon's, Who Needs Failure? Nov 13
- Lexicon Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 12
- LEXICON PHARMACEUTICALS, INC./DE Files SEC form 8-K, Results of Operations and Financial Condition, Financial Stateme Nov 12
- Q3 2013 Lexicon Pharmaceuticals Inc. Earnings Release - Before Market Open Nov 12
LXRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Lexicon Pharmaceuticals is up 13.08% over the last year vs S&P 500 Total Return up 29.68%, Achillion Pharmaceuticals down 55.76%, and Sarepta Therapeutics down 34.97%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for LXRX
Pro Report PDF for LXRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download LXRX Pro Report PDF
Pro Strategies Featuring LXRX
Did Lexicon Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Lexicon Pharmaceuticals, Inc., operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease.